Home > Publications Database > Novelty-Related fMRI Responses of Precuneus and Medial Temporal Regions in Individuals at Risk for Alzheimer Disease. > print

001     165172
005     20240826165947.0
024 7 _ |a 10.1212/WNL.0000000000200667
|2 doi
024 7 _ |a pmid:35995589
|2 pmid
024 7 _ |a pmc:PMC9484732
|2 pmc
024 7 _ |a 0028-3878
|2 ISSN
024 7 _ |a 1526-632X
|2 ISSN
024 7 _ |a altmetric:129431067
|2 altmetric
037 _ _ |a DZNE-2022-01474
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Billette, Ornella V
|0 P:(DE-2719)2810799
|b 0
|e First author
|u dzne
245 _ _ |a Novelty-Related fMRI Responses of Precuneus and Medial Temporal Regions in Individuals at Risk for Alzheimer Disease.
260 _ _ |a [S.l.]
|c 2022
|b Ovid
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1709566963_22644
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a We assessed whether novelty-related fMRI activity in medial temporal lobe regions and the precuneus follows an inverted U-shaped pattern across the clinical spectrum of increased Alzheimer disease (AD) risk as previously suggested. Specifically, we tested for potentially increased activity in individuals with a higher AD risk due to subjective cognitive decline (SCD) or mild cognitive impairment (MCI). We further tested whether activity differences related to diagnostic groups were accounted for by CSF markers of AD or brain atrophy.We studied 499 participants aged 60-88 years from the German Center for Neurodegenerative Diseases Longitudinal Cognitive Impairment and Dementia Study (DELCODE) who underwent task-fMRI. Participants included 163 cognitively normal (healthy control, HC) individuals, 222 SCD, 82 MCI, and 32 patients with clinical diagnosis of mild AD. CSF levels of β-amyloid 42/40 ratio and phosphorylated-tau181 were available from 232 participants. We used region-based analyses to assess novelty-related activity (novel > highly familiar scenes) in entorhinal cortex, hippocampus, and precuneus as well as whole-brain voxel-wise analyses. First, general linear models tested differences in fMRI activity between participant groups. Complementary regression models tested quadratic relationships between memory impairment and activity. Second, relationships of activity with AD CSF biomarkers and brain volume were analyzed. Analyses were controlled for age, sex, study site, and education.In the precuneus, we observed an inverted U-shaped pattern of novelty-related activity across groups, with higher activity in SCD and MCI compared with HC, but not in patients with AD who showed relatively lower activity than MCI. This nonlinear pattern was confirmed by a quadratic relationship between memory impairment and precuneus activity. Precuneus activity was not related to AD biomarkers or brain volume. In contrast to the precuneus, hippocampal activity was reduced in AD dementia compared with all other groups and related to AD biomarkers.Novelty-related activity in the precuneus follows a nonlinear pattern across the clinical spectrum of increased AD risk. Although the underlying mechanism remains unclear, increased precuneus activity might represent an early signature of memory impairment. Our results highlight the nonlinearity of activity alterations that should be considered in clinical trials using functional outcome measures or targeting hyperactivity.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Amyloid beta-Peptides
|2 NLM Chemicals
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 2 |a Alzheimer Disease: diagnosis
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides
|2 MeSH
650 _ 2 |a Biomarkers
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: diagnostic imaging
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Magnetic Resonance Imaging: methods
|2 MeSH
650 _ 2 |a Parietal Lobe: diagnostic imaging
|2 MeSH
650 _ 2 |a Temporal Lobe: diagnostic imaging
|2 MeSH
693 _ _ |0 EXP:(DE-2719)DELCODE-20140101
|5 EXP:(DE-2719)DELCODE-20140101
|e Longitudinal Cognitive Impairment and Dementia Study
|x 0
700 1 _ |a Ziegler, Gabriel
|0 P:(DE-2719)2814076
|b 1
|u dzne
700 1 _ |a Aruci, Merita
|b 2
700 1 _ |a Schütze, Hartmut
|0 P:(DE-2719)9001467
|b 3
|u dzne
700 1 _ |a Kizilirmak, Jasmin M
|0 P:(DE-2719)9000615
|b 4
|u dzne
700 1 _ |a Richter, Anni
|0 0000-0001-9681-6298
|b 5
700 1 _ |a Altenstein, Slawek
|0 P:(DE-2719)2811720
|b 6
|u dzne
700 1 _ |a Bartels, Claudia
|0 P:(DE-2719)9000444
|b 7
|u dzne
700 1 _ |a Brosseron, Frederic
|0 P:(DE-2719)2810593
|b 8
|u dzne
700 1 _ |a Cardenas-Blanco, Arturo
|0 P:(DE-2719)2810750
|b 9
|u dzne
700 1 _ |a Dahmen, Philip
|0 P:(DE-2719)9001698
|b 10
|u dzne
700 1 _ |a Dechent, Peter
|b 11
700 1 _ |a Dobisch, Laura
|0 P:(DE-2719)2811611
|b 12
|u dzne
700 1 _ |a Fliessbach, Klaus
|0 P:(DE-2719)2811326
|b 13
|u dzne
700 1 _ |a Freiesleben, Silka Dawn
|0 P:(DE-2719)2812392
|b 14
|u dzne
700 1 _ |a Glanz, Wenzel
|0 P:(DE-2719)2811614
|b 15
|u dzne
700 1 _ |a Göerß, Doreen
|b 16
700 1 _ |a Haynes, John Dylan
|b 17
700 1 _ |a Heneka, Michael T
|0 P:(DE-2719)2000008
|b 18
|u dzne
700 1 _ |a Kilimann, Ingo
|0 P:(DE-2719)2810394
|b 19
|u dzne
700 1 _ |a Kimmich, Okka
|b 20
700 1 _ |a Kleineidam, Luca
|0 P:(DE-2719)2812139
|b 21
|u dzne
700 1 _ |a Laske, Christoph
|0 P:(DE-2719)2000055
|b 22
|u dzne
700 1 _ |a Lohse, Andrea
|0 P:(DE-2719)2811189
|b 23
|u dzne
700 1 _ |a Rostamzadeh, Ayda
|b 24
700 1 _ |a Metzger, Coraline
|0 P:(DE-2719)9000443
|b 25
|u dzne
700 1 _ |a Munk, Matthias H
|0 P:(DE-2719)9001516
|b 26
|u dzne
700 1 _ |a Peters, Oliver
|0 P:(DE-2719)2811024
|b 27
|u dzne
700 1 _ |a Preis, Lukas
|0 P:(DE-2719)9000703
|b 28
|u dzne
700 1 _ |a Priller, Josef
|0 P:(DE-2719)2811122
|b 29
|u dzne
700 1 _ |a Scheffler, Klaus
|0 0000-0001-6316-8773
|b 30
700 1 _ |a Schneider, Anja
|0 P:(DE-2719)2812035
|b 31
|u dzne
700 1 _ |a Spottke, Annika
|0 P:(DE-2719)2811324
|b 32
|u dzne
700 1 _ |a Spruth, Eike Jakob
|0 P:(DE-2719)2812446
|b 33
|u dzne
700 1 _ |a Ramirez, Alfredo
|0 P:(DE-2719)2812825
|b 34
|u dzne
700 1 _ |a Röske, Sandra
|0 P:(DE-2719)2810395
|b 35
|u dzne
700 1 _ |a Roy, Nina
|0 P:(DE-2719)2812341
|b 36
|u dzne
700 1 _ |a Teipel, Stefan
|0 P:(DE-2719)2000026
|b 37
|u dzne
700 1 _ |a Wagner, Michael
|0 P:(DE-2719)2000057
|b 38
|u dzne
700 1 _ |a Wiltfang, Jens
|0 P:(DE-2719)2811317
|b 39
|u dzne
700 1 _ |a Wolfsgruber, Steffen
|0 P:(DE-2719)2810544
|b 40
|u dzne
700 1 _ |a Yakupov, Renat
|0 P:(DE-2719)2812398
|b 41
|u dzne
700 1 _ |a Zeidman, Peter
|b 42
700 1 _ |a Jessen, Frank
|0 P:(DE-2719)2000032
|b 43
|u dzne
700 1 _ |a Schott, Björn
|0 P:(DE-2719)2814326
|b 44
|u dzne
700 1 _ |a Düzel, Emrah
|0 P:(DE-2719)2000005
|b 45
|u dzne
700 1 _ |a Maass, Anne
|0 P:(DE-2719)2811815
|b 46
|e Last author
|u dzne
700 1 _ |a Group, DELCODE Study
|b 47
|e Collaboration Author
773 _ _ |a 10.1212/WNL.0000000000200667
|g Vol. 99, no. 8, p. e775 - e788
|0 PERI:(DE-600)1491874-2
|n 8
|p e775 - e788
|t Neurology
|v 99
|y 2022
|x 0028-3878
856 4 _ |u https://pub.dzne.de/record/165172/files/DZNE-2022-01474.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/165172/files/DZNE-2022-01474.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:165172
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2810799
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2814076
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 3
|6 P:(DE-2719)9001467
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)9000615
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2811720
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 7
|6 P:(DE-2719)9000444
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)2810593
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2810750
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)9001698
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 12
|6 P:(DE-2719)2811611
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 13
|6 P:(DE-2719)2811326
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 14
|6 P:(DE-2719)2812392
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 15
|6 P:(DE-2719)2811614
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 18
|6 P:(DE-2719)2000008
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 19
|6 P:(DE-2719)2810394
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 21
|6 P:(DE-2719)2812139
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 22
|6 P:(DE-2719)2000055
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 23
|6 P:(DE-2719)2811189
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 25
|6 P:(DE-2719)9000443
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 26
|6 P:(DE-2719)9001516
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 27
|6 P:(DE-2719)2811024
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 28
|6 P:(DE-2719)9000703
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 29
|6 P:(DE-2719)2811122
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 31
|6 P:(DE-2719)2812035
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 32
|6 P:(DE-2719)2811324
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 33
|6 P:(DE-2719)2812446
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 34
|6 P:(DE-2719)2812825
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 35
|6 P:(DE-2719)2810395
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 36
|6 P:(DE-2719)2812341
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 37
|6 P:(DE-2719)2000026
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 38
|6 P:(DE-2719)2000057
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 39
|6 P:(DE-2719)2811317
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 40
|6 P:(DE-2719)2810544
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 41
|6 P:(DE-2719)2812398
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 43
|6 P:(DE-2719)2000032
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 44
|6 P:(DE-2719)2814326
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 45
|6 P:(DE-2719)2000005
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 46
|6 P:(DE-2719)2811815
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 1
914 1 _ |y 2022
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-27
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
|0 LIC:(DE-HGF)CCBYNCND4
|2 HGFVOC
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-27
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-27
915 _ _ |a Allianz-Lizenz
|0 StatID:(DE-HGF)0410
|2 StatID
|d 2022-11-12
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-12
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEUROLOGY : 2021
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-12
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b NEUROLOGY : 2021
|d 2022-11-12
920 1 _ |0 I:(DE-2719)1311001
|k AG Maaß
|l Multimodal Neuroimaging
|x 0
920 1 _ |0 I:(DE-2719)5000006
|k AG Düzel
|l Clinical Neurophysiology and Memory
|x 1
920 1 _ |0 I:(DE-2719)1410006
|k AG Wiltfang
|l Molecular biomarkers for predictive diagnostics of neurodegenerative diseases
|x 2
920 1 _ |0 I:(DE-2719)1811005
|k AG Endres
|l Interdisciplinary Dementia Research
|x 3
920 1 _ |0 I:(DE-2719)1011301
|k Biomarker
|l Interventional Trials and Biomarkers in Neurodegenerative Diseases
|x 4
920 1 _ |0 I:(DE-2719)1340009
|k AG Speck
|l Linking imaging projects iNET
|x 5
920 1 _ |0 I:(DE-2719)5000000
|k AG Peters
|l Biomarker-Assisted Early Detection of Dementias
|x 6
920 1 _ |0 I:(DE-2719)1011101
|k Patient Studies Bonn
|l Patient Studies Bonn
|x 7
920 1 _ |0 I:(DE-2719)1340013
|k KAP
|l Cooperation Unit for Applied Prevention Research (KAP)
|x 8
920 1 _ |0 I:(DE-2719)1510100
|k AG Teipel
|l Clinical Dementia Research (Rostock /Greifswald)
|x 9
920 1 _ |0 I:(DE-2719)1210000
|k AG Gasser
|l Parkinson Genetics
|x 10
920 1 _ |0 I:(DE-2719)5000007
|k AG Priller
|l Translational Neuropsychiatry
|x 11
920 1 _ |0 I:(DE-2719)1011201
|k AG Wagner
|l Neuropsychology
|x 12
920 1 _ |0 I:(DE-2719)1011401
|k Clinical Research Platform (CRP)
|l Clinical Research Platform (CRP)
|x 13
920 1 _ |0 I:(DE-2719)1011001
|k AG Klockgether
|l Patient Studies
|x 14
920 1 _ |0 I:(DE-2719)1011305
|k AG Schneider
|l Translational Dementia Research (Bonn)
|x 15
920 1 _ |0 I:(DE-2719)1011102
|k AG Jessen
|l Clinical Alzheimer’s Disease Research
|x 16
920 1 _ |0 I:(DE-2719)1410002
|k AG Fischer
|l Epigenetics and Systems Medicine in Neurodegenerative Diseases
|x 17
920 1 _ |0 I:(DE-2719)5000034
|k Delcode
|l Delcode
|x 18
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1311001
980 _ _ |a I:(DE-2719)5000006
980 _ _ |a I:(DE-2719)1410006
980 _ _ |a I:(DE-2719)1811005
980 _ _ |a I:(DE-2719)1011301
980 _ _ |a I:(DE-2719)1340009
980 _ _ |a I:(DE-2719)5000000
980 _ _ |a I:(DE-2719)1011101
980 _ _ |a I:(DE-2719)1340013
980 _ _ |a I:(DE-2719)1510100
980 _ _ |a I:(DE-2719)1210000
980 _ _ |a I:(DE-2719)5000007
980 _ _ |a I:(DE-2719)1011201
980 _ _ |a I:(DE-2719)1011401
980 _ _ |a I:(DE-2719)1011001
980 _ _ |a I:(DE-2719)1011305
980 _ _ |a I:(DE-2719)1011102
980 _ _ |a I:(DE-2719)1410002
980 _ _ |a I:(DE-2719)5000034
980 _ _ |a UNRESTRICTED
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21